PHAROS Trial Dashboard
Phase 2 open-label PHAROS study — encorafenib + binimetinib in BRAF V600-mutant metastatic NSCLC. A narrow patient population, but clinically relevant. ORR: 75% in treatment-naïve patients, 46% in previously treated. Dashboard covers both cohorts, tumour genomics, and safety data.
Challenge
BRAF V600 mutation in NSCLC is uncommon — the clinical community needed a clear evidence summary without digging through journal articles. Presenting two cohorts (naïve vs. pre-treated) comparably without cluttering the layout was the main design problem.
Solution
Separated cohort data visually while keeping key metrics side by side for a quick read. The tumour genomics section lets users dig into mutation profiles; safety uses a standard AE table format that oncologists already know.
Role
Data Analyst
Year
2023